ReviewOncogene2017
The role of claudins in cancer metastasis.
Review in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 191 citations in OpenAlex.
- Structure-forward targeting of claudins with synthetic binders.FEBS letters · 2026Review
- CLDN7: Epithelial gatekeeper from physiology to pathology‑roles in cancer and epithelial‑related diseases (Review).International journal of molecular medicine · 2026Review
- Knocking down CLDN7 enhanced the effect of cisplatin in OC cells by regulating mitophagy.Journal of ovarian research · 2026Article
- Pathological and therapeutic implications of Notch overexpression in claudin-low breast cancers.Human cell · 2026Article
- The Age of Molecular Biomarkers: Cancer in the Era of Personalized Medicine. What Do Pathologists in Developing Countries Need to Know and Understand?International journal of general medicine · 2026Review
- FAT2 inhibits breast cancer cell migration, invasion, and epithelial-mesenchymal transition through transcriptional upregulation of CLDN19.Frontiers in oncology · 2026Article
- The claudin family characteristics in pan-cancer and the role of claudin12 in the malignant progression of lung adenocarcinoma.Scientific reports · 2025Article
- Promotional effects of aged ZnO nanoparticles on migration, invasion and metastasis of human breast cancer MCF-7 cellsBiochemistry and biophysics reports · 2025Article
- The research trends and hotspots of claudins in the field of cancer.Cell adhesion & migration · 2025Review
- Enhancing targeted delivery and efficacy of PEGylated liposomal doxorubicin with liposomal minoxidil: comprehensive in silico, in vitro, and in vivo tumor model studies.Drug delivery · 2025Article
- AOH induces oxidative stress and DNA damage in ovarian cancer cells via modulation of GPER1 and HIF1α/PI3K/CLDNs signaling pathway.Scientific reports · 2025Article
- A Novel Tight Junction-Nuclear Receptor Signaling Pathway Regulating Cancer Progression.Pathology international · 2025Review
- 3D collagen high-throughput screen identifies drugs that induce epithelial polarity and enhance chemotherapy response in colorectal cancer.Communications biology · 2025Article
- IgSF11-RAP1 signaling promotes cell migration and invasion of cutaneous melanoma.Cell communication and signaling : CCS · 2025Article
- Comprehensive analysis reveals CLDN9 is a new biomarker in human cancers and immunotherapeutic target for glioblastoma multiforme.Cancer cell international · 2025Article
- Claudin-11 Enhances Invasive and Metastatic Abilities of Small-Cell Lung Cancer Through MT1-MMP Activation.Cancer science · 2025Article
- HIF-1α-Mediated Disruption of Cellular Junctions: The Impact of Hypoxia on the Tumor Microenvironment and Invasion.International journal of molecular sciences · 2025Review
- UDP-glycosyltransferases alleviate the toxic effects of deoxynivalenol on the growth performance and gut damage of Kunming mice.Scientific reports · 2025Article
- Claudin-9 (Cancer pathogenesis and therapy · 2025Article
- Bioinformatics-Driven Investigations of Signature Biomarkers for Triple-Negative Breast Cancer.Bioinformatics and biology insights · 2025Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
TJs are large intercellular adhesion complexes that maintain cell polarity in normal epithelia and endothelia. During the metastatic process, TJs must be 'loosened' or dismantled in cancer cells to enable migration and dissemination. Diminished TJ integrity must also occur within endothelial cells to allow intravasation and extravasation of cancer cells across endothelial barriers. Claudins are critical components of TJs, forming homo- and heteromeric interactions between the adjacent cells, which have been implicated as key modulators of carcinogenesis and metastasis. Numerous epithelial-derived cancers display altered claudin expression patterns and certain claudins can now be used as biomarkers to predict patient prognosis. Moreover, claudins have been functionally implicated in numerous steps of the metastatic cascade. The distinct roles played by claudins during the cancer progression to metastatic disease are just starting to be elucidated. A more complete understanding of the mechanisms through which claudins augment cancer metastasis is required to develop new therapeutic agents against this family of proteins. In this review, we will summarize the relationship between the claudin expression and clinical outcomes in diverse cancers, discuss tumor intrinisic roles through which claudins regulate metastasis and explore claudin-mediated functions within stromal cells that influence the metastatic process. Finally, we will consider possible strategies for targeting claudins that have the potential to improve the management of metastatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.